Combination Medication Therapy for High-Quality Cryopreservation

While Human Cryopreservation holds tremendous potential it is still a majorly underfunded sector of the longevity and life extension ecosystem. Even comparatively modest funding amounts can lead to significant and relevant impact. One low-hanging fruit are medication stabilization protocols. There are three challenges with contemporary human cryopreservation medication stabilization protocols. Despite the long lists of medications that have been used in cryonics protocols, pilot experiments have shown that only sodium citrate and heparin confer clear benefits on mitigating ischemia-induced perfusion impairment. In ideal circumstances, these compounds are administered right after circulatory arrest because they are estimated to lose their efficacy between 15 and 30 minutes post-mortem. Timely administration would be further favored if the effective compounds are combined in one, simple-to-administer, aqueous solution. For this solution to be practical and permit wide-spread local distribution in the field, it would not include any (regulated) pharmaceuticals but just a solution of chemicals that are readily available.

We propose to research, develop, and validate a solution that consists of at least one antithrombotic agent, one non-anesthetic compound that depresses brain metabolism, and one neuroprotectant. This solution can be administered immediately after pronouncement of legal death. We aim to validate this solution in an in-situ rat brain cryopreservation model with elimination of ice formation as a clinical endpoint. Our model provides for a non-ischemic control, an experimental group of 2 hours of normothermic ischemia, and a 2 normothermic ischemia experimental group in which we administer the solution. We expect to see significant improvement in mitigation of perfusion impairment and reduction of ice formation after cryopreservation in the group that received the multi-model solution immediately upon death. Successful development and validation of such a multi-modal solution would strongly streamline and simplify cryonics stabilization procedures and even hold promise for the treatment of out-of-hospital cardiac arrest and stroke in mainstream medicine. Positive results could be the base for novel IP regarding formulation and/or delivery methods to improve cryopreservation quality. Preliminary data shows that a few of the tested components have beneficial effects on the sub-factors determining preservation quality. Results from the proposed study will provide critical preclinical IP to support commercializing a Combination Medication Therapy for High-Quality Cryopreservation, which the investigator(s) intend do with support from CryoDAO.